NRSNW and H1Z Related Headlines
Go Back- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense receives US patent for Alzheimer's treatment through 2043
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
NRSNW and H1Z Related Press Releases
Go Back- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
